Kerendia Special Precautions

Hyperkalaemia: Hyperkalaemia has been observed in patients treated with KERENDIA.
Some patients are at a higher risk to develop hyperkalaemia. Risk factors include low eGFR, higher serum potassium and previous episodes of hyperkalaemia. Consider more frequent monitoring in these patients.
Initiation of KERENDIA treatment is not recommended if serum potassium >5.0 mmol/L.
If serum potassium >4.8 to 5.0 mmol/L, initiation of KERENDIA treatment may be considered with additional serum potassium monitoring within the first 4 weeks based on patient characteristics and serum potassium levels (see Dosage & Administration).
Withhold KERENDIA in treated patients if serum potassium >5.5 mmol/L. Follow local guidelines for the management of hyperkalaemia. Restart KERENDIA at 10 mg once daily if serum potassium ≤5.0 mmol/L (see Dosage & Administration).
Remeasure serum potassium and eGFR in all patients 4 weeks after initiation or restart or up-titration of KERENDIA treatment. Thereafter, remeasure serum potassium periodically and as needed based on patient characteristics and serum potassium levels (see Dosage & Administration).
Concomitant medications: The risk of hyperkalaemia also may increase with the intake of concomitant medications that may increase serum potassium (see Interactions). See also Concomitant use of substances that affect finerenone exposure as follows.
Avoid concomitant use of KERENDIA with the following medications: potassium-sparing diuretics (e.g., amiloride, triamterene); other mineralocorticoid receptor antagonists (MRAs) (e.g., eplerenone, spironolactone).
Use KERENDIA with caution and monitor serum potassium when taken concomitantly with the following medications: potassium supplements; trimethoprim, or trimethoprim-sulfamethoxazole. Temporary discontinuation of KERENDIA may be necessary.
Use in Hepatic Impairment: Patients with severe hepatic impairment (Child Pugh C) have not been studied (see Pharmacology: Pharmacokinetics under Actions). Due to an expected significant increase in finerenone exposure, avoid use of KERENDIA in patients with severe hepatic impairment (see Dosage & Administration).
Due to an increase in finerenone exposure, consider additional serum potassium monitoring and adapt monitoring according to patient characteristics in patients with moderate hepatic impairment (Child Pugh B) (see Dosage & Administration and Pharmacology: Pharmacokinetics under Actions).
Use in Renal Impairment: The risk of hyperkalaemia increases with decreasing renal function. Ongoing monitoring of renal function should be performed as needed according to standard practice (see Dosage & Administration).
Initiation of KERENDIA treatment is not recommended in patients with eGFR <25 mL/min/1.73 m² as clinical experience is limited (see Dosage & Administration and Pharmacology: Pharmacokinetics under Actions).
Continue KERENDIA treatment with caution regarding serum potassium levels in patients with end-stage renal disease (eGFR <15 mL/min/1.73 m²) as clinical experience is limited (see Dosage & Administration).
Effects on Laboratory Tests: See Adverse Reactions, Tables 3 and 5, and Pharmacology: Pharmacodynamics: Clinical Trials under Actions.
Embryo-foetal toxicity: Animal data have shown reproductive toxicity. The relevance for humans is unknown. KERENDIA should not be used during pregnancy unless there has been careful consideration of the benefit for the mother and the risk to the foetus. If the patient becomes pregnant while taking KERENDIA, the patient should be informed of potential risks to the foetus. Advise women of childbearing potential to use effective contraception during treatment with KERENDIA. Advise women not to breastfeed during treatment with KERENDIA (see Use in Pregnancy & Lactation).
Concomitant use of substances that affect finerenone exposure: Moderate and weak CYP3A4 inhibitors: The concomitant use of KERENDIA with moderate CYP3A4 inhibitors (e.g., erythromycin and verapamil) and weak CYP3A4 inhibitors (e.g., amiodarone and fluvoxamine) is expected to increase finerenone exposure (see Interactions). Monitor serum potassium especially during initiation of or changes to dosing of KERENDIA or the CYP3A4 inhibitor (see Dosage & Administration).
Strong and moderate CYP3A4 inducers: Avoid concomitant use of KERENDIA with strong CYP3A4 inducers (e.g., rifampicin, carbamazepine, phenytoin, phenobarbital, St John's Wort) or moderate CYP3A4 inducers (e.g., efavirenz), which are expected to markedly decrease finerenone plasma concentrations and result in reduced therapeutic effect (see Interactions). Consider selection of an alternate concomitant medicinal product with no or weak potential to induce CYP3A4.
Grapefruit: Avoid concomitant intake of grapefruit or grapefruit juice as it is expected to increase the plasma concentration of finerenone (see Dosage & Administration and Interactions).
Effects on Ability to Drive and Use Machines: No effects on ability to drive and use machines have been observed.
Use in the Elderly: No dose adjustment is required in the elderly (see Pharmacology: Pharmacokinetics under Actions).
Use in Children: The safety and efficacy of KERENDIA have not been established in patients under 18 years of age. Therefore, KERENDIA is not recommended for use in paediatric patients.